Targeted therapies registered so far in NSCLC by the FDA and/or EMA target nine different oncoproteins, encoded by the genes ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1–3, RET, ROS1 [29]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.